Abstract: Microcontroller-driven battery management systems (BMS) are crucial for various applications, including electric vehicles, portable electronics, and renewable energy storage. These systems ...
Hosted on MSN
I made a glowing face mask with LEDs!
Let's make a Face Mask with LEDs! **Materials:** - Individually addressable LED strip soldered in a 30 x 12 LED grid - Arduino Micro - SD card reader module - Push button - 10,000 mAh power bank - ...
Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos faces new competition. A year ago, in the first quarter of 2025, BMS’ ...
The partnership aims to leverage AI-powered workflows across trial design, drafting, validation, and optimization processes. (iStock / Getty Images Plus) Bristol Myers Squibb has tapped up Faro to use ...
Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy continues to struggle with uptake. Bristol Myers Squibb sales hit $12.5 ...
Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...
On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...
The PD.Charger-GSM v2.5 is an industrial-grade solar and LiFePo4 charger/controller with MPPT support, designed for 2–4 cell Li-Ion/LiFePo4 batteries. With various connectivity options and a ...
Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study ...
Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results